F.D.A. Authorizes a New Covid Drug to Protect High-Risk People
Pemgarda, available in the coming weeks, is intended for immunocompromised people who are unlikely to mount an adequate response after vaccination.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.